22,000
employees
150
Close to 140 countries where the Group’s
medicines are distributed
20%
Over 20% of revenue from
brand-name medicines invested
in R&D each year
€ 5.9 billion
euros in revenue in 2022/2023
including €4.5 billion for brand-name medicines
and €1.4 billion for generic activities
5 therapeutic areas
Neuropsychiatry, Venous diseases,
Cardiovascular, Diabetes
and Oncology